# Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-8b813e20
Ticker: SLDB
Company: Solid Biosciences
Source: Solid Biosciences
Published: 2026-06-01 20:05 EST
## Summary

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision...

## Article Body
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com .

Solid Biosciences Investor Contact: Nicole Anderson Senior Director, Investor Relations and Corporate Communications Solid Biosciences Inc. investors@solidbio.com
## Recent Company News
- 2026-06-01 20:05 EST — [Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-8b813e20) — Source: Solid Biosciences
- 2026-06-01 12:00 EST — [Solid Biosciences to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/SLDB/solid-biosciences-to-participate-at-upcoming-investor-conferences-2a3e1bc2) — Source: Solid Biosciences
- 2026-05-12 20:08 EST — [Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-busi-5df78103) — Source: Solid Biosciences
- 2026-05-07 12:00 EST — [Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/SLDB/solid-biosciences-doses-first-participant-in-phase-3-impact-duchenne-clinical-tr-0b3eb7cf) — Source: Solid Biosciences
- 2026-05-01 20:05 EST — [Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-e564b5de) — Source: Solid Biosciences
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)